Cookies


ESHRE ® uses cookies to improve your browsing experience on its website, as defined in the Cookie Policy (as updated on 18/03/2024). Strictly necessary cookies are necessary for the proper functioning of the Website – therefore, you cannot refuse them. Other, non-strictly necessary cookies are only placed if you consent to their use. Read more about it in our Cookie Policy. Do you agree with our use of non-strictly necessary cookies?
Manage my cookie preferences

Immunomodulation during ART. A thing of the past or the answer to optimise treatment outcomes?

Precongress Course 11

SIG Safety and Quality in ART Special Interest Group Safety Quality in ART


Course co-ordinators
Zdravka Veleva (Finland), Alessandra Alteri (Italy), Samuel dos Santos-Ribeiro (Portugal)

Course type
Advanced

Course description
The immune system plays a central role during pregnancy. Immunomodulation is a rapidly developing addition to ART treatments. This precongress course will provide a comprehensive overview of the role of the immune system at conception and on the empirical use and safety of immune drugs in recurrent implantation failure. We will explore novel aspects of immunological profiling in oocyte donation, inflammation, microbiota and the state of endometrial immune system.

Target audience
ART practitioners, basic scientists, students, embryologists

Educational needs and expected outcomes
The safety aspects and real-life applications of immunomodulation have not been presented in depth before. This precongress course is a much-needed update.

Participants will learn details on the four aspects of immunomodulation during ART:

  • Basic information and potential applications;
  • Information on when it is clearly of clinical importance;
  • Potential new applications;
  • Potential risks. 

Innovative aspects of the course
First immunomodulation course.

Programme



Sunday 29 June 2025

09:00 - 09:30
’overview of the immune response to conception and implantation
Sarah A. Robertson, Australia
09:30 - 09:45
Discussion
09:45 - 10:00
Can we be incompatible? Male/female autoimmunity
Speaker invited, but not confirmed
10:15 - 10:30
Discussion
10:30 - 11:00
Coffee break
11:00 - 11:30
Empirical use of immune drugs. What does the guideline suggest? (about RIF guideline)
Speaker invited, but not confirmed
11:30 - 11:45
Discussion
11:45 - 12:15
Safety of immune therapies
Sarah A. Robertson, Australia
12:15 - 12:30
Discussion
12:30 - 13:30
Lunch break
13:30 - 14:00
Oocyte donation profiling (to include KIR/HLA-C profiling. pros and cons)
Speaker to be announced
14:00 - 14:15
Discussion
14:15 - 14:45
KIR/HLA-C profiling and possible strategies in autologous patients
Speaker invited, but not confirmed
14:45 - 15:00
Discussion
15:00 - 15:30
Coffee break
15:30 - 16:00
Uterine NK cells environment in endometrium
Nathalie Lédée, France
16:00 - 16:15
Discussion
16:15 - 16:45
Chronic endometritis and microbiota assessment - is it something real?
José Antonio Horcajadas Almansa, Spain
16:45 - 17:00
Discussion